sandwich enzyme assay on the Bayer Immuno 1 analyzer. The IMx ® PSA Assay (Abbott Laboratories) is a microparticle enzyme immunoassay on the Abbott IMx analyzer. The Tandem ® -R PSA immunoradiometric assay (Hybritech, Inc.) is a solid-phase double antibody sandwich assay that utilizes two noncompeting mouse monoclonal antibodies. The PSA-2 assay is a fully automated assay that uses a monoclonal-polyclonal antibody sandwich assay format on the ACS TM :180 system (Ciba Corning Diagnostics). The TOSOH AIA (Tosoh Medics) method is a two-site immunoenzymometric assay that uses magnetic bead technology and utilizes two monoclonal antibodies.
Reference materials were obtained from the College of American Pathologists (CAP). CAP Proficiency Survey Samples (K series samples K-06, K-07, and K-08, 1996) are made from semen-supplemented human plasma and contain at least 50% free PSA (12) . CAP-Certified Reference Material is made from human serum from donors, which was blended to target values of 0.5, 4.0, and 9.0 g/L. This material contains ϳ90% complexed PSA and 10% free PSA (12) . To investigate the effect of varying proportions of free and complexed PSA on PSA quantitation by the different assays, test materials containing five mixtures of both free PSA and PSA-ACT (Scripps Laboratories, San Diego, CA) were prepared at Bayer Corporation. Mixtures of seminal purified PSA and PSA-ACT were prepared at 4 g/L total PSA in several ratios of free PSA to PSA-ACT complex (100:0, 80:20, 50:50, 20:80, and 0:100). The mixtures were prepared with a buffer containing 60 g/L bovine serum albumin, 111 mmol/L sodium chloride, 25 mmol/L Tris, 1 g/L sodium azide, and 2 g/L Proclin-150, pH 7.4. PSA in the free and complexed PSA preparations was measured on the Bayer Immuno 1 analyzer. Measurements of free and complexed PSA, using the Bayer assay calibrators, agree with values obtained with PSA standards measured by biophysical means (11) .
The study was conducted at the following six clinical laboratories: Providence St. Vincent Medical Center (Portland, OR), V.A. Puget Sound Health Care (Seattle, WA), University Hospital (State University of New York, Stony Brook, NY), Memorial Sloan Kettering Cancer Center (New York, NY), Hospital of University of Pennsylvania (Philadelphia, PA), and Huntsville Hospital (Huntsville, AL). Each site measured PSA recoveries from the three test materials, using the Immuno 1 assay. Two of these sites also measured PSA in the test samples, using the Tandem R, IMx, and the TOSOH AIA methods. One of the sites measured PSA with the ACS:180 assay. Test samples were analyzed in duplicate in a single run for each of the immunoassays evaluated in the study. Commercial controls were included in each run to validate method and instrument performance. All assays were performed according to manufacturers' instructions.
The amounts of PSA recovered when test material mixtures containing five different ratios of free PSA to PSA-ACT complex were assayed are presented in Fig. 1 . The Bayer Immuno 1 assay was unaffected by changing proportions of PSA complexed to ACT and had an equimolar response to both free and ACT-complexed
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Clinical Chemistry 44, No. 7, 1998 PSA. The TOSOH assay also had an equimolar response to both free and ACT-complexed PSA, but gave slightly lower PSA values compared with the Immuno 1 assay. In contrast, the responses of the IMx and the ACS:180 assays were greater at high proportions of free PSA and decreased markedly as the proportion of complexed PSA increased in the test sample. The Hybritech Tandem-R assay had a lower assay response at high concentrations of free PSA, which increased as the proportion of complexed PSA in the test sample increased. PSA measured by the Hybritech assay was Ͻ4 g/L at all proportions of free and complexed PSA. Agreement between PSA values for the different methods improved as the proportion of complexed PSA increased in the test samples.
The mean PSA values determined for each of the five immunoassays, using the CAP Proficiency Survey K series samples and the CAP-Certified Reference series, are shown in Table 1 . Recoveries of PSA from CAP Proficiency Survey samples by the five methods showed large intermethod differences. In contrast to the large intermethod variation in PSA values using the CAP K series, PSA values generated using CAP Certified Reference Material by the five methods produced very similar results.
CAP Proficiency Survey samples are semen-supplemented human plasma containing at least 50% PSA in the uncomplexed form. When we tested synthetic mixtures with similar proportions of uncomplexed PSA, we found large intermethod differences in the quantitation of total PSA. In contrast, with CAP Reference serum, which is composed of blended human serum that contains the majority of PSA in the complexed form (ϳ90% complexed, 10% free PSA), PSA values measured by the different methods were similar. Synthetic mixtures of 80% complexed and 20% free PSA, with proportions of PSA forms similar to those found in CAP reference serum, generated similar PSA values by the different methods ( Fig. 1 ).
Similar to our findings, Garg et al. (12) reported similar PSA values with the TOSOH, Abbott IMx, and Hybritech assays for CAP reference serum, but strikingly different PSA values for proficiency survey samples. Similarly, Stamey (8) , comparing immunoassays by use of mixtures of free and complexed PSA in which the total concentration of PSA was the same, reported that the Hybritech Tandem-R assay measured low values when the proportion of free PSA was Ͼ50%. In addition, the IMx and ACS:180 assays measured high PSA values when mixtures contained 25% free PSA and increased markedly as the proportion of free PSA increased in the test samples. The TOSOH method generated an equimolar response to free and complexed PSA.
In a recent study, Blase et al. (13) measured synthetic mixtures with varying proportions of seminal fluidderived free PSA, using five different immunoassays, and reported findings similar to ours. In a subsequent study, that group showed that the skewed response observed in nonequimolar assays is reflected in patient sera (14) . They compared the ratio of PSA values reported with a skewed assay to PSA values reported with an equimolar assay as a function of the mean PSA concentration of patient samples grouped by the proportion of free PSA. The results showed that skewed assays overrecover PSA from serum samples with increased proportions of free PSA. Other studies have demonstrated that commercially available immunoassays vary in their responsiveness to free and complexed PSA in clinical specimens (7, 8, 10, 15) . Jacobsen et al. (15) measured PSA in serum from healthy men, using the Hybritech Tandem-R and the IMx assay. Although the 
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Technical Briefs two methods correlated well, the IMx assay gave higher PSA values at high ratios and lower PSA values at low ratios of free-to-total PSA. Zhou et al. (7) found that the ACS:180 PSA-2 assay measured PSA from patients with prostate cancer and BPH up to three times higher than did the Hybritech Tandem-R method. It has been suggested that PSA measurements using synthetic mixtures with varying proportions of free and ACT-bound PSA may not reflect results in patient sera (16) . However, results from the studies presented suggest that free PSA values can vary in patients' sera, and measurements with skewed assays may compromise the clinical utility of PSA measurements. The proportion of free PSA in serum may reach as high as 55% (3, 7) . In the studies reported here and elsewhere (8, 12, 13) , at high proportions of free PSA, PSA values do not agree among manufacturers. Because the proportion of free PSA tends to be high in men who do not have prostate cancer, serum from such individuals could give falsely high PSA values in skewed response assays.
The comparison of results for CAP Proficiency samples with the ACS;180, PSA-2, IMx, and Bayer Immuno 1 PSA assays are consistent with the results shown in Fig. 1 . An exception, however, is the finding that the Hybritech and TOSOH assay values were higher than the Bayer Immuno 1 assay values for the CAP K series but lower for the synthetic mixtures. This may reflect the fact that different isoforms of free PSA have been reported in seminal fluid (17) . Values may differ from assay to assay because antibodies differ in their recognition of the different isoforms of PSA (17) . PSA is quite different in serum.
In an effort to standardize PSA, it has been suggested that standard reference material containing 90% ACTcomplexed and 10% free PSA be used to bring commercial immunoassays closer to concordance (8, 12) . This ratio was chosen because it closely mimics the ratio of free and complexed PSA found in clinical specimens. However, skewed response assays such as the IMx, ACS:180, and Hybritech-Tandem R assay will accurately measure PSA values only when the PSA forms in serum samples approximate a 90:10 ratio. Deviations from this ratio in the PSA forms, as demonstrated in this study, will generate inaccurate PSA values by these assays. The use of reference material containing the 90:10 ratio of complexed-tofree PSA will minimize the intermethod variation among manufacturers but will not solve the underlying problem: Commercial assays report different values for clinical specimens because of differences in responses to free and complexed PSA. The only way to accurately standardize PSA assays is to use two standards, one with low free PSA and one with high free PSA.
Stenman et al. (18) suggest that because the proportion of free and complexed PSA differs between benign and malignant diseases, a goal for standardization of total PSA assays should be the detection of free and ACT-complexed PSA on an equimolar basis. However, at present, this may be an unachievable goal because of the varied responses of different immunoassays to the different forms of PSA. As an alternative, manufacturers can de-velop new generation tests that measure the individual forms of PSA (6, 7, 12) . For example, a new generation of automated assay has recently been described, which measures complexed PSA selectively, and has been reported to increase the diagnostic specificity for patients with BPH (19) . This test alone could improve the distinction between prostate cancer and BPH without having to measure both free and total PSA. Clinical trials will determine the usefulness of these assays in detecting and monitoring prostate cancer patients.
Portions of this work were previously presented in abstract form [Clin Chem 1997;43(Suppl 6):S137]. We gratefully acknowledge Dr. Glen Armstrong for review of the manuscript.
